National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 2 of 2 Research Studies DisplayedLyons TW, Johnson KB, Michelson KA
Yield of emergent neuroimaging in children with new-onset seizure and status epilepticus.
The purpose of this paper was to determine the yield of emergent neuroimaging among children with new-onset seizures presenting with status epilepticus. The authors found that a substantial minority of children with new-onset seizures presenting with status epilepticus have urgent or emergent intracranial pathology identified on neuroimaging and that magnetic resonance imaging is the preferred imaging modality when available and safe.
AHRQ-funded; HS000063.
Citation: Lyons TW, Johnson KB, Michelson KA .
Yield of emergent neuroimaging in children with new-onset seizure and status epilepticus.
Seizure 2016 Feb;35:4-10. doi: 10.1016/j.seizure.2015.12.009.
.
.
Keywords: Children/Adolescents, Diagnostic Safety and Quality, Imaging, Neurological Disorders, Outcomes, Patient-Centered Outcomes Research
Lyerly MJ, Houston JT, Boehme AK
Safety of intravenous tissue plasminogen activator administration with computed tomography evidence of prior infarction.
The researchers sought to determine if the presence of a previous stroke on pretreatment computed tomography (CT) is a predictor of hemorrhagic complications and functional outcomes after the administration of intravenous (IV) tissue plasminogen activator (tPA). Their data suggest that a prior stroke on CT should not be viewed as a reason to withhold this treatment unless it occurred within the last 3 months.
AHRQ-funded; HS013852.
Citation: Lyerly MJ, Houston JT, Boehme AK .
Safety of intravenous tissue plasminogen activator administration with computed tomography evidence of prior infarction.
J Stroke Cerebrovasc Dis 2014 Jul;23(6):1657-61. doi: 10.1016/j.jstrokecerebrovasdis.2014.01.011..
Keywords: Stroke, Risk, Outcomes, Imaging